Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210612421> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4210612421 endingPage "86" @default.
- W4210612421 startingPage "83" @default.
- W4210612421 abstract "Abstract Indolent non-Hodgkin lymphoma (iNHL), including follicular (FL) and marginal zone (MZL) lymphoma, now enjoy durable disease control with first-line immunochemotherapy, with a median overall survival (OS) of over 15 years in most series (Kahl and Yang 2016). However, iNHL is still widely considered incurable in most cases, and disease history remains characterized by a relapsing and remitting course, with each remission period shorter than the previous one, and OS and progression-free survival (PFS) decrease with each subsequent line of conventional therapy (Batlevi et al. 2020). Patients with unmet needs include approximately 20% of FL patients who experience disease progression within 24 months (POD24) after initial chemoimmunotherapy (with a 5-year OS of 48% (Casulo et al. 2015)—although it remains unclear how much this worse outcome is driven by misdiagnosed transformed follicular lymphoma (Freeman et al. 2019)) and those who fail multiple regimens (5-year PFS of 23%) (Rivas-Delgado et al. 2019) have double refractory disease (Gopal et al. 2017) or experience relapse after autologous stem cell transplantation (ASCT) (Sesques et al. 2020). Although promising results were obtained with an immunomodulatory regimen combining anti-C20 Moab and lenalidomide (Leonard et al. 2019; Morschhauser et al. 2019), most current approved therapies do not overcome incremental disease resistance, resulting in multiple lines of treatment with cumulative toxicity over a patient’s lifetime. The autologous anti-CD19 chimeric antigen receptor T cell (CAR-T) therapies tisa-cel and axi-cel, which are now approved for patients with relapsed/refractory (r/r) large B cell lymphoma (LBCL), have also been tested in iNHL, with promising results." @default.
- W4210612421 created "2022-02-08" @default.
- W4210612421 creator A5051605599 @default.
- W4210612421 creator A5091882595 @default.
- W4210612421 date "2022-01-01" @default.
- W4210612421 modified "2023-09-30" @default.
- W4210612421 title "Indolent Lymphomas" @default.
- W4210612421 cites W2160093471 @default.
- W4210612421 cites W2335468012 @default.
- W4210612421 cites W2597471357 @default.
- W4210612421 cites W2623935289 @default.
- W4210612421 cites W2773804840 @default.
- W4210612421 cites W2902226821 @default.
- W4210612421 cites W2903225254 @default.
- W4210612421 cites W2925270992 @default.
- W4210612421 cites W2951145881 @default.
- W4210612421 cites W2956178192 @default.
- W4210612421 cites W2962056638 @default.
- W4210612421 cites W3043738734 @default.
- W4210612421 cites W3095414066 @default.
- W4210612421 cites W3096548119 @default.
- W4210612421 cites W3097467929 @default.
- W4210612421 cites W3097923020 @default.
- W4210612421 cites W3113332039 @default.
- W4210612421 doi "https://doi.org/10.1007/978-3-030-94353-0_15" @default.
- W4210612421 hasPublicationYear "2022" @default.
- W4210612421 type Work @default.
- W4210612421 citedByCount "0" @default.
- W4210612421 crossrefType "book-chapter" @default.
- W4210612421 hasAuthorship W4210612421A5051605599 @default.
- W4210612421 hasAuthorship W4210612421A5091882595 @default.
- W4210612421 hasBestOaLocation W42106124211 @default.
- W4210612421 hasConcept C121332964 @default.
- W4210612421 hasConcept C126322002 @default.
- W4210612421 hasConcept C142424586 @default.
- W4210612421 hasConcept C143998085 @default.
- W4210612421 hasConcept C2776063141 @default.
- W4210612421 hasConcept C2776364478 @default.
- W4210612421 hasConcept C2777058707 @default.
- W4210612421 hasConcept C2779050716 @default.
- W4210612421 hasConcept C2779338263 @default.
- W4210612421 hasConcept C2780653079 @default.
- W4210612421 hasConcept C2780790343 @default.
- W4210612421 hasConcept C2781413609 @default.
- W4210612421 hasConcept C71924100 @default.
- W4210612421 hasConcept C87355193 @default.
- W4210612421 hasConceptScore W4210612421C121332964 @default.
- W4210612421 hasConceptScore W4210612421C126322002 @default.
- W4210612421 hasConceptScore W4210612421C142424586 @default.
- W4210612421 hasConceptScore W4210612421C143998085 @default.
- W4210612421 hasConceptScore W4210612421C2776063141 @default.
- W4210612421 hasConceptScore W4210612421C2776364478 @default.
- W4210612421 hasConceptScore W4210612421C2777058707 @default.
- W4210612421 hasConceptScore W4210612421C2779050716 @default.
- W4210612421 hasConceptScore W4210612421C2779338263 @default.
- W4210612421 hasConceptScore W4210612421C2780653079 @default.
- W4210612421 hasConceptScore W4210612421C2780790343 @default.
- W4210612421 hasConceptScore W4210612421C2781413609 @default.
- W4210612421 hasConceptScore W4210612421C71924100 @default.
- W4210612421 hasConceptScore W4210612421C87355193 @default.
- W4210612421 hasFunder F4320310646 @default.
- W4210612421 hasFunder F4320313342 @default.
- W4210612421 hasLocation W42106124211 @default.
- W4210612421 hasOpenAccess W4210612421 @default.
- W4210612421 hasPrimaryLocation W42106124211 @default.
- W4210612421 hasRelatedWork W2067618106 @default.
- W4210612421 hasRelatedWork W2102241654 @default.
- W4210612421 hasRelatedWork W2308455367 @default.
- W4210612421 hasRelatedWork W2733909589 @default.
- W4210612421 hasRelatedWork W2795268657 @default.
- W4210612421 hasRelatedWork W2951033984 @default.
- W4210612421 hasRelatedWork W2981884153 @default.
- W4210612421 hasRelatedWork W3014926372 @default.
- W4210612421 hasRelatedWork W3197673475 @default.
- W4210612421 hasRelatedWork W4237492816 @default.
- W4210612421 isParatext "false" @default.
- W4210612421 isRetracted "false" @default.
- W4210612421 workType "book-chapter" @default.